Premium
Reduced long‐term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report
Author(s) -
Edell Dean,
Bruce Erik,
Hale Kathe,
Edell Debra,
Khoshoo Vikram
Publication year - 1998
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/(sici)1099-0496(199803)25:3<154::aid-ppul4>3.0.co;2-m
Subject(s) - ribavirin , medicine , bronchiolitis , respiratory system , pneumovirus , respiratory disease , airway , pediatrics , paramyxoviridae , virus , viral disease , anesthesia , immunology , lung , hepatitis c virus
Previously healthy infants less than 6 months of age with severe respiratory syncytial virus bronchiolitis who required hospitalization were identified from hospital records. Infants had been treated either conservatively (control group, n = 19) or with ribavirin added to conservative management (study group, n = 22). All infants underwent a 1‐year follow‐up after the initial illness. There was a significant reduction in the prevalence of reactive airway disease in the group treated with ribavirin (P < 0.05) compared with the control group, both in terms of the proportion of patients developing airway reactivity (59% vs. 89%) and the number of episodes of reactive airway disease (31 vs. 70). Our data suggest that ribavirin reduces the prevalence of airway reactivity. Pediatr. Pulmonol. 1998; 25:154–158. © 1998 Wiley‐Liss, Inc.